Definium Therapeutics, Inc. (DFTX) Discusses Phase III Clinical Progress and Study Outcomes for Lead Program in Mood Disorders Transcript

Paul Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division

All right. Awesome. Thanks so much, everybody. Always a pleasure to be moderating a discussion for Rob Barrow, CEO of Definium. I’m sure people who are dialing in here mostly know the story, but maybe Rob can give us sort of a quick snapshot of where you guys are at. Maybe talk about some of the data you generated this year with 120, the upcoming readout that we’re going to dig into pretty deeply and some of the nuances there. So Rob, thanks again. Always good to see you, and yes, take it away.

Robert Barrow
CEO & Director

Yes. Likewise, thanks so much for having us. It’s been an incredibly exciting summer. So our lead program, DT120 is an ODT form of LSD we’re developing in generalized anxiety disorder, major depressive disorder. 2024, we had landmark results. First study readout for this molecule in this program in generalized anxiety disorder where we saw an incredibly large effect size 12 weeks after a single treatment effect size of 0.81, a demonstrated dose response and then we kicked off a Phase III program.

And based on those data, we kicked off the program in GAD and in MDD. First data we had this summer in June were from Emerge, MDD Pivotal study, where we saw an effect size of 0.81 and 8.1 on the MADRS separation about 6 or 8 weeks later in August, we had a second Phase III readout, our first GAD readout in Phase III VOYAGE where we